trending Market Intelligence /marketintelligence/en/news-insights/trending/CcfZDFnCf_BOwkp2MT7xUA2 content esgSubNav
In This List

Alexion CEO, CFO step down


Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective

Alexion CEO, CFO step down

Alexion Pharmaceuticals appointed David Brennan and David Anderson interim CEO and CFO, respectively.

Brennan previously served as CEO and executive director of AstraZeneca PLC and has been a member of Alexion's board since July 2014. He succeeds David Hallal, who left the company for personal reasons and also stepped down from Alexion's board.

Further, Anderson, who was previously the senior vice president and CFO of Honeywell, succeeds Vikas Sinha, who resigned as CFO to pursue other opportunities.

Both appointments are effective immediately.

Meanwhile, Alexion said its previously announced audit and finance committee investigation is nearing completion but has not yet identified any facts that would require the company to update its previously reported historical results.

The company previously said it would postpone the release of its financial statement for the quarter ended Sept. 30 as it conducted a probe into a former employee's allegations in relation to its sales practices for Soliris.